Harmony Biosciences LLC, a new company created by entrepreneur Jeff Aronin's Paragon Biosciences, has acquired exclusive U.S. rights to a drug already EMA-approved for adults with narcolepsy, from France's Bioprojet Societe Civile de Recherche. Harmony is fueling the deal with a $270 million equity financing that it said will also help accelerate its ability to advance other treatments for central nervous system disorders. Meanwhile, it intends to establish an expanded access program for the medicine, called pitolisant, in the U.S. in early 2018 and to submit an FDA new drug application for it during the first half of 2018.